<?xml version="1.0" encoding="UTF-8"?>
<p id="Par9">The second top-ranked drug is 
 <italic>tafenoquine</italic> which is an orally active 8-aminoquinoline, a long-acting analog of primaquine, antimalarialÂ medicine developed by GlaxoSmithKline and 60 Degrees Pharmaceuticals (Baird 
 <xref ref-type="bibr" rid="CR4">2018</xref>; Frampton 
 <xref ref-type="bibr" rid="CR12">2018</xref>). The drug was FDA approved for the radical cure of 
 <italic>Plasmodium vivax</italic> (
 <italic>P. vivax</italic>) malaria and the prophylaxis of malaria in 2018. The drug is active against pre-erythrocytic, erythrocytic forms and the gametocytes of Plasmodium species that include 
 <italic>P. falciparum</italic> and 
 <italic>P. vivax</italic> (Baird 
 <xref ref-type="bibr" rid="CR4">2018</xref>; Frampton 
 <xref ref-type="bibr" rid="CR12">2018</xref>). Clinical trials for this drug may be also recommended. Chloroquine, which is an antimalaria and immunosuppressive drug, has been recently shown to improve the outcomes in patients with the novel coronavirus pneumonia, which made the FDA issue an Emergency Use Authorization to be tested as a treatment for COVID-19, ranked at the fourth position in this study (Gao et al. 
 <xref ref-type="bibr" rid="CR13">2020</xref>).
</p>
